Comparative Study on Hand Eczema Treatments
Background
Hand eczema is a common skin condition that affects many people and reduces their quality of life. Topical medications, like Clobetasol Propionate, are often used but may cause side effects with long-term use. This study will compare the effectiveness of two treatments: topical Tofacitinib 2% ointment and Clobetasol Propionate 0.05% ointment.
Methods
This research will take place at the Dermatology department of Acharya Vinoba Bhave Rural Hospital in India from March 2023 to September 2025. Participants diagnosed with hand eczema will be randomly assigned to two groups:
- Group 1: Receives Clobetasol Propionate 0.05% ointment
- Group 2: Receives Tofacitinib 2% ointment
The main goal is to evaluate changes in the severity of hand eczema using the Hand Eczema Severity Index (HECSI) score at two and four weeks. Statistical analysis will be performed to determine the significance of the results.
Expected Outcome
This study aims to shed light on how Tofacitinib compares to Clobetasol Propionate for treating hand eczema. If Tofacitinib proves effective, it could serve as a better alternative with fewer side effects. The results could lead to improved treatment options and ongoing research in dermatology.
Practical Solutions and Value
Clinical trials are essential for finding safe and effective treatments. Our platform, DocSym, leverages AI to centralize clinical standards and research, making it easy for healthcare providers to access important information.
In a fast-paced healthcare setting, streamlining processes is vital. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine services, improving patient care management.
By incorporating AI technology, clinics can optimize workflows, enhance patient outcomes, and minimize paperwork. Discover how we can assist you at aidevmd.com.